title: [Valproic acid pharmacogenetics in an individual approach to treatment of women of childbearing age with epilepsy].
abstract: A clinical case of the development of undesirable pharmacological phenomena in a woman of childbearing age with epilepsy is described. The development of undesirable pharmacological phenomena at reception of average therapeutic doses of valproic acid has been caused by the primary (idiopathic) and secondary (valproate-induced) infringement of a folic cycle against a combination of CYP2C9*3 gene polymorphism and a mutation in the MTHFR gene.
authors.forename: N A
authors.initials: NA
authors.lastname: Snaĭder
authors.forename: D A
authors.initials: DA
authors.lastname: Sychev
authors.forename: M S
authors.initials: MS
authors.lastname: Piliugina
authors.forename: D V
authors.initials: DV
authors.lastname: Dmitrenko
authors.forename: E N
authors.initials: EN
authors.lastname: Bochanova
authors.forename: E A
authors.initials: EA
authors.lastname: Shapovalova
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005298:Fertility; D005492:Folic Acid / Q000008:administration & dosage / Q000378:metabolism; D005494:Folic Acid Deficiency / Q000139:chemically induced* / Q000235:genetics*; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D009154:Mutation; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid; D005492:Folic Acid; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D042965:Methylenetetrahydrofolate Reductase (NADPH2)